Literature DB >> 9864204

Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice.

N B Saunders1, D R Shoemaker, B L Brandt, E E Moran, T Larsen, W D Zollinger.   

Abstract

Colonization of the human nasopharyngeal region by Neisseria meningitidis is believed to lead to natural immunity. Although the presence of bactericidal antibody in serum has been correlated with immunity to meningococcal disease, mucosal immunity at the portal of entry may also play an important role. This study was undertaken to examine in mice the possibility of safely using native outer membrane vesicles (NOMV) not exposed to detergent as an intranasal (i.n.) vaccine. The mucosal and systemic responses of mice to intranasal and intraperitoneal (i.p.) vaccination with NOMV were compared over a range of doses from 0.1 to 20 microgram. Intranasal vaccination of mice with NOMV induced a strong systemic bactericidal antibody response, as well as a strong local immunoglobulin A immune response in the lung as determined by assay of lung lavage fluid by enzyme-linked immunosorbent assay and lung antibody secreting cells by enzyme-linked immunospot assay. However, 8- to 10-fold-higher doses of NOMV were required i.n. compared to i.p. to elicit an equivalent bactericidal antibody response in serum. Some NOMV vaccine was aspirated into the lungs of mice during i.n. immunization and resulted in an acute inflammatory response that peaked at 1 to 2 days postimmunization and was cleared by day 7. These results indicate that i.n. delivery of meningococcal NOMV in mice is highly effective in eliciting the production of both a mucosal immune response and a systemic bactericidal antibody response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9864204      PMCID: PMC96285     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Protective studies with a group A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the upper respiratory tract.

Authors:  S M Polly; R H Waldman; P High; M K Wittner; A Dorfman
Journal:  J Infect Dis       Date:  1975-03       Impact factor: 5.226

2.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

3.  Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity.

Authors:  E E Moran; B L Brandt; W D Zollinger
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

4.  A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells.

Authors:  J D Sedgwick; P G Holt
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

5.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.

Authors:  C C Czerkinsky; L A Nilsson; H Nygren; O Ouchterlony; A Tarkowski
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.

Authors:  W D Zollinger; R E Mandrell; J M Griffiss; P Altieri; S Berman
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

7.  Attachment of Neisseria meningitidis to human mucosal surfaces: influence of pili and type of receptor cell.

Authors:  D S Stephens; Z A McGee
Journal:  J Infect Dis       Date:  1981-04       Impact factor: 5.226

8.  Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus.

Authors:  R D'Alessandri; G Plotkin; R M Kluge; M K Wittner; E N Fox; A Dorfman; R H Waldman
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

9.  A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies.

Authors:  W D Zollinger; J W Boslego
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

10.  Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection.

Authors:  R Weltzin; H Kleanthous; F Guirakhoo; T P Monath; C K Lee
Journal:  Vaccine       Date:  1997-03       Impact factor: 3.641

View more
  28 in total

1.  Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.

Authors:  Rohit K Katial; Brenda L Brandt; Ellen E Moran; Stephen Marks; Victor Agnello; Wendell D Zollinger
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination.

Authors:  Makda Fisseha; Ping Chen; Brenda Brandt; Todd Kijek; Elizabeth Moran; Wendell Zollinger
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.

Authors:  Wendell D Zollinger; Elizabeth E Moran; Deborah H Schmiel
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

Review 4.  Virulence and immunomodulatory roles of bacterial outer membrane vesicles.

Authors:  Terri N Ellis; Meta J Kuehn
Journal:  Microbiol Mol Biol Rev       Date:  2010-03       Impact factor: 11.056

5.  Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits.

Authors:  David R Shoemaker; Nancy B Saunders; Brenda L Brandt; E Ellen Moran; Andrew D Laclair; Wendell D Zollinger
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Authors:  L Goetsch; A Gonzalez; H Plotnicky-Gilquin; J F Haeuw; J P Aubry; A Beck; J Y Bonnefoy; N Corvaïa
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

7.  Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Authors:  Deborah H Schmiel; Elizabeth E Moran; Paul B Keiser; Brenda L Brandt; Wendell D Zollinger
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

8.  Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines.

Authors:  Libuse Janakova; Hilde Bakke; Inger Lise Haugen; Aud K H Berstad; E Arne Høiby; Ingeborg S Aaberge; Bjørn Haneberg
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice.

Authors:  Stefan Schild; Eric J Nelson; Andrew Camilli
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

10.  Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants.

Authors:  Mark B Stoddard; Valerian Pinto; Paul B Keiser; Wendell Zollinger
Journal:  Clin Vaccine Immunol       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.